Scope
Reference
C346388
Description
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
Commercial tool
Establishes a framework
Total value (estimated)
- £1,516,353,164 excluding VAT
- £1,819,623,796 including VAT
Above the relevant threshold
Contract dates (estimated)
- 1 December 2025 to 31 May 2027
- Possible extension to 31 May 2029
- 3 years, 6 months
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
- 33690000 - Various medicinal products
Contract locations
- UK - United Kingdom
Engagement
Engagement deadline
11 April 2025
Engagement process description
NHS England is pleased to invite suppliers to a virtual 1:1 preliminary market engagement meeting in relation to the upcoming re-tender of the Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines Framework. The purpose of the sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, clinical aspects and KPI's. Please contact b.kullootee@nhs.net or michelle.clarke6@nhs.net to register your interest. There will also be a 7 day window for queries to be raised in writing after all sessions have concluded.
Participation
Particular suitability
Small and medium-sized enterprises (SME)
Submission
Publication date of tender notice (estimated)
2 June 2025
Contracting authority
NHS England
- Public Procurement Organisation Number: PDPT-3135-BWWY
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
United Kingdom
Region: UKI45 - Lambeth
Organisation type: Public authority - central government